Abstract: A light-emitting device, a light-emitting substrate, and a method for manufacturing the light-emitting device. The light-emitting device includes at least one light-emitting structure. The light-emitting structure includes: a first semiconductor layer; a light-emitting layer; a second semiconductor layer, doping ions of the second semiconductor layer and a first semiconductor layer being oppositely charged; a barrier structure provided with an opening for exposing the second semiconductor layer, the orthographic projection of the opening on the base substrate being located in the orthographic projection of the light-emitting layer on the base substrate, and the area of the opening being smaller than that of the light-emitting layer; and a landing electrode located on the side of the barrier structure facing away from the second semiconductor layer, the landing electrode being in contact with the second semiconductor layer by means of the opening.

Abstract: Among the various aspects of the present disclosure is the provision of compositions and methods of treating or preventing various headache disorders or neuropathic pain by increasing the number of Treg cells in a subject. In particular, low dose IL-2, rapamycin, statin or Treg cell administration are shown to be useful in treating or preventing headache or neuropathic pain.

Abstract: Methods, systems, and circuits for training a neural network include applying noise to a set of training data across wordlines using a respective noise switch on each wordline. A neural network is trained using the noise-applied training data to generate a classifier that is robust against adversarial training.

Abstract: The present disclosure provides a device and methods for determining the original stratum direction of a core. The device includes a confining pressure pump, a resistance meter, and a core holder composed of upper and lower portions. The present disclosure further provides three methods for determining the original stratum direction of the core. The three methods respectively use the device to measure resistance values at different positions of the core, and compare a test result with an imaging result of resistivity imaging logging data to determine the rock direction of the core in a stratum.

Abstract: Disclosed herein are compounds of formula I and/or a stereoisomer, stable isotopologue, and/or pharmaceutically acceptable salts thereof; and therapeutic uses of these compounds, which are inhibitors of tryptophan 2, 3-dioxygenase 2 (TDO2) and/or indoleamine 2, 3-dioxygenase 1 (IDO1), potentially useful in the treatment of diseases treatable, such as cancers.

Abstract: The present disclosure relates to a 2K coating composition comprising a polysiloxane-modified polyurethane and a hardener, wherein the polysiloxane-modified polyurethane obtainable by a method comprising the following steps: a) subjecting a polyol to a reaction with an isocyanate-functional silane coupling agent to obtain a silane-grafted polyol, and b) subjecting the silane-grafted polyol to a condensation reaction with a hydroxyl-functional polysiloxane, to obtain the polysiloxane-modified polyurethane. The polysiloxane-modified polyurethane can be used in a coating composition to form a coating which has smooth feel, stain resistance and easy clean properties, particularly desired in the field of e.g. consumer electronics and automotive industry.

Abstract: A speed reducer, a power system, a straddle-type rail train, and a rail transport system are disclosed. The speed reducer includes: a box body; a speed-reducing mechanism, disposed in the box body; and a support shaft, a first end of the support shaft being supported on the box body, and a second end of the support shaft being connected to a high-speed end of the speed-reducing mechanism. The speed reducer according to the present disclosure achieves a more stable connection between a drive shaft and a speed-reducing mechanism and a more stable power transmission.

Abstract: (I) Disclosed herein are compounds of formula I, and/or a stereoisomer, a stable isotope, or a pharmaceutically acceptable salt or solvate thereof; and therapeutic uses of these compounds, which are inhibitors of rearranged during transfection (RET), potentially useful in the treatment of RET-associated diseases, such as RET-associated cancers.

Abstract: A locking device comprising: first and second flanges; and first and second flange locking structures. The first and second flange locking structures are used for selectively locking the first flange and the second flange. Each flange locking structure comprises: a synchronising ring and a driving assembly. The synchronising ring is able to slide relative to the corresponding flange; and the drive assembly is capable of selectively pushing the synchronising ring to slide along the axial direction of the corresponding flange from an unlocked position to a locked position.

Abstract: (I) Disclosed herein are compounds of formula I, and/or a stereoisomer, a stable isotope, or a pharmaceutically acceptable salt thereof; and therapeutic uses of these compounds, which are kinase inhibitors potentially useful in the treatment of diseases treatable, such as cancers, as well as pharmaceutical compositions, comprising a compound of formula I, and/or a stereoisomer, a stable isotope, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

Abstract: The present disclosure relates to a 2K coating composition comprising a polysiloxane-modified polyurethane and a hardener, wherein the polysiloxane-modified polyurethane obtainable by a method comprising the following steps: a) subjecting a polyol to a reaction with an isocyanate-functional silane coupling agent to obtain a silane-grafted polyol, and b) subjecting the silane-grafted polyol to a condensation reaction with a hydroxyl-functional polysiloxane, to obtain the polysiloxane-modified polyurethane. The polysiloxane-modified polyurethane can be used in a coating composition to form a coating which has smooth feel, stain resistance and easy clean properties, particularly desired in the field of e.g. consumer electronics and automotive industry.

Abstract: A speed reducer, a power system, a straddle-type rail train, and a rail transport system are disclosed. The speed reducer includes: a box body; a speed-reducing mechanism, disposed in the box body; and a support shaft, a first end of the support shaft being supported on the box body, and a second end of the support shaft being connected to a high-speed end of the speed-reducing mechanism. The speed reducer according to the present disclosure achieves a more stable connection between a drive shaft and a speed-reducing mechanism and a more stable power transmission.

Abstract: The present invention discloses a locking device, a power assembly, a power transmission system and a vehicle. The locking device includes: a first flange, the first flange being adapted to be fixed on the first shaft; a second flange, the second flange being adapted to be fixed on the second shaft; a synchronizing ring, the synchronizing ring being normally connected to the first flange to be adapted to rotate synchronously with the first flange, and the synchronizing ring being slidable relative to the first flange; and a driving component, the driving component selectively pushing the synchronizing ring to slide from an unlocked position to a locked position in an axial direction of the first flange. When the synchronizing ring is in the locked position, the synchronizing ring is connected to the second flange be adapted to rotate the second flange synchronously with the first flange. When the synchronizing ring is in the unlocked position, the synchronizing ring is separated from the second flange.

Abstract: The present disclosure provides a compound of Formula (I) and/or a stereoisomer, a tautomer, a stable isotope, or a pharmaceutically acceptable salt thereof; and therapeutic uses of these compounds. They are kinase inhibitors potentially useful in the treatment of diseases treatable, such as cancers. Also disclosed herein is a pharmaceutical composition, comprising a compound of Formula (I) and/or a stereoisomer, a tautomer, a stable isotope, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.

Abstract: Methods, systems, and circuits for training a neural network include applying noise to a set of training data across wordlines using a respective noise switch on each wordline. A neural network is trained using the noise-applied training data to generate a classifier that is robust against adversarial training.

Abstract: Disclosed herein are compounds of formula I and/or a stereoisomer, stable isotopologue, and/or pharmaceutically acceptable salts thereof; and therapeutic uses of these compounds, which are inhibitors of tryptophan 2, 3-dioxygenase 2 (TDO2) and/or indoleamine 2, 3-dioxygenase 1 (IDO1), potentially useful in the treatment of diseases treatable, such as cancers.

Abstract: Techniques facilitating matrix multiplication on a systolic array are provided. A computer-implemented method can comprise populating, by a system operatively coupled to a processor, respective first registers of one or more processing elements of a systolic array structure with respective input data bits of a first data matrix. The one or more processing elements can comprise a first processing element that comprises a first input data bit of the first data matrix and a first activation bit of a second data matrix. The method can also include determining, by the system, at the first processing element, a first partial sum of a third data matrix. Further, the method can include streaming, by the system, the first partial sum of the third data matrix from the first processing element.

Abstract: (I) Disclosed herein are compounds of formula I, and/or a stereoisomer, a stable isotope, or a pharmaceutically acceptable salt thereof; and therapeutic uses of these compounds, which are kinase inhibitors potentially useful in the treatment of diseases treatable, such as cancers, as well as pharmaceutical compositions, comprising a compound of formula I, and/or a stereoisomer, a stable isotope, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

Abstract: A tadalafil orally dissolving film and a preparation method thereof are provided. The tadalafil orally dissolving film consisting of specific components is prepared through a conventional process. Particularly, the tadalafil orally dissolving film is prepared by tadalafil, film-forming material, plasticizer, correctant, colorant and aromatic, wherein the film-forming material includes components of: (a) at least one member selected from polysaccharide; (b) at least one member selected from organic acid; and (c) at least one member selected from hydroxyalkyl cellulose. Compared with prior art, the tadalafil orally dissolving film provided by the present invention has an easy preparation process, no specific requirement on production devices and a storing stability, and is easy to reproduce, has a low requirement on storage conditions, and is easy to package, transport and store.

Abstract: Disclosed herein is a compound of formula (I) and/or a pharmaceutically acceptable salt thereof that can serve as Erk inhibitors. They are potentially useful in the treatment of diseases treatable by inhibition of Erk, such as cancers. Also disclosed herein is a pharmaceutical composition, comprising a compound of formula I and/or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.